The shares of NEXGEL Inc. (NASD: NXGL) traded 16.90% higher in after-hours trading, recovering from a regular-session loss of -10.12%. There were 14.8K shares traded in the regular sessions.
NXGL recently announced what?
NXGEL (NXGL) last week announced that its CEO, Adam Levy, will participate at LD Micro’s Main Event XV Conference in Los Angeles, California and Dawson James Securities’ 7th Annual Small Cap Growth Conference in Jupiter, Florida in October.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
- At Wyndham Grand Hotel in Jupiter, Florida, Dawson James Securities will hold its 7th Annual Small Cap Growth Conference on Wednesday, October 12th, 2022. NXGL CEO will present on the day at 5:00 PM ET.
- On Tuesday, October 26th, Mr. Levy will take part in LD Micro Main Event XV, taking place at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
A recent accomplishment of NXGL:
As part of its announcement last week, NexGEL (NXGL) announced that SAGE Journals’ Scars, Burns and Healing publication, a peer-reviewed journal devoted to scar and burn research, published new data on the impact SilverSeal hydrogel dressings had on postoperative scarring and complications. Patients treated with SilverSeal experienced significant scar improvement.
How was the study designed by NXGL?
NEXGEL evaluated the effectiveness of SilverSeal as an antimicrobial dressing post-surgery. A double-blind, randomized study with 20 patients in each group included 40 foot and ankle patients ages 32 to 66. A SilverSeal hydrogel dressing was given to the treatment group after surgery, and a petroleum-based dressing was given to the control group.
NXGL has observed what?
Compared to the control group, patients in the treatment group reported significantly less pain at 12 weeks, indicating statistically significant improvements in the POSAS observer score and observer opinion. Both groups reported decreased itching at the surgical site over time, with the treatment group reporting significantly less itching. After six and 12 weeks, scarring was significantly reduced in the treatment group in comparison to the control group. There were no postoperative complications in either group.
What impact will NXGL results have on treatments?
Patients in the hydrogel group experienced a significant decrease in skin and scar incisional pain, which was observed throughout the study, according to NEXGEL (NXGL). Encouraging results by NXGL suggest a marked change in how patients undergoing surgery should be treated. They are promising for both foot and ankle surgery and healing all postoperative incisions as well.
